Innovent Biologics estimates ~50% jump in 2025 revenue
Source: SeekingAlpha
2025-08-27 06:28:01 ET
More on Innovent Biologics
- Neutral On Innovent Biologics: Hard To Justify Its Premium
- How mazdutide compares against weight loss therapies from Novo Nordisk, Lilly
- Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
- Historical earnings data for Innovent Biologics
- Financial information for Innovent Biologics
Read the full article on Seeking Alpha
For further details see:
Innovent Biologics estimates ~50% jump in 2025 revenue
Innovent Biologics Inc
NASDAQ: IVBXF
IVBXF Trading
-1.43% G/L:
$10.094 Last:
794 Volume:
$9.776 Open:
IVBXF Latest News
June 06, 2026 01:52:00 pm
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
